PARP1 and cancer: Previously, some investigations demonstrated that genetic alteration of the PARP1 Val762Ala can modulate cancer susceptibility, and that the frequency of the Ala/Ala genotype was significantly higher in patients when compared with controls [7], [9], [13], [24], [43] with one exception, in which its frequency was found to be significantly lower in patients [21].